Ebusco Holding N.V. (AMS:EBUS)
Netherlands · Delayed Price · Currency is EUR 0.3388
+0.0026 (0.77%)
Aug 1, 2025, 5:35 PM CET
Achilles Therapeutics Revenue
In the year 2024, Ebusco Holding had annual revenue of 10.67M EUR, down -89.59%. Ebusco Holding had revenue of -27.34M in the half year ending December 31, 2024, a decrease of -136.68%.
Revenue
10.67M
Revenue Growth
-89.59%
P/S Ratio
2.58
Revenue / Employee
20.43K
Employees
522
Market Cap
27.50M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.67M | -91.78M | -89.59% |
| Dec 31, 2023 | 102.44M | -9.18M | -8.22% |
| Dec 31, 2022 | 111.62M | 87.35M | 359.99% |
| Dec 31, 2021 | 24.27M | -75.73M | -75.73% |
| Dec 31, 2020 | 99.99M | 51.07M | 104.39% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionEbusco Holding News
- 11 months ago - Christian Schreyer Takes the Helm at Ebusco as Founders Peter Bijvelds and Michiel Peters Step Down as Co-CEOs - CEOWORLD magazine